Company intelligence / Profile preview

Shanghai Fuhong Biopharmaceutical Co., Ltd.

Ownership: Private
Development stage: Commercial

Overview

The company’s lead asset FH‑006 targets malignant solid neoplasms and has reached Phase 2 clinical trials. The company specializes in developing monoclonal antibody drugs for cancer treatment. It was established as a joint venture with Fosun Pharma and an American scientist team to leverage advanced US biomedicine R&D and production technologies.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesbiological products
Industry: Biotech

Drug pipeline

3 assets

rituximab

Commercial

Indications: Non-Hodgkin lymphoma

2 more assets in the full pipeline.

Request access →

Partnerships

Joint venture with Fosun Pharma and an American scientist team for mAb developmentCollaboration with Jiangsu Hengrui Pharmaceuticals on pipeline assets

Beyond the preview

Go deeper on Shanghai Fuhong Biopharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Fuhong Biopharmaceutical Co., Ltd..

Explore the full profile